NICE accepts golimumab in rheumatoid arthritis

NICE has recommended golimumab (Simponi), in combination with methotrexate, as another option for the treatment of active rheumatoid arthritis. Like other tumour necrosis factor (TNF) inhibitors, it can be considered for use in patients with:

  • a disease activity score greater than 5.1 on two separate occasions at least 1 month apart, who have undergone trials of two conventional DMARDs, including methotrexate (unless contraindicated), or
  • severe rheumatoid arthritis, who have inadequately responded to other DMARDs, including at least one TNF inhibitor, and for whom rituximab is inappropriate.

NICE approval of golimumab is contingent on the manufacturer supplying the 100mg dose, which should be considered for use in patients >100kg, at the same price as the 50mg dose.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases